Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00800982 · ClinicalTrials.gov registry record · NA
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis
A NA study of Psoriasis, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00800982: Completed NA study of Psoriasis, sponsored by University of California, San Francisco.
NCT00800982 is a NA study of Psoriasis that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00800982, a NA study of Psoriasis, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, open-label, pilot study. A total of 30 subjects (15 in each study arm) will be enrolled in this 6 month study to evaluate whether the addition of narrow band UVB (NB-UVB) phototherapy can enhance the efficacy of etanercept's maintenance dose, 50 mg once a week, in obese psoriasis patients.
Primary Outcome
Psoriasis area severity index was used to determine the number of patients in each treatment arm who had 75% improvement in their psoriasis. This scale uses the characteristics of the psoriasis, such as body surface area, redness, thickness, and scaling, to determine the severity score.
Conditions Studied
Interventions
- PROCEDURE Narrow band (310-312 nm) ultraviolet light B phototherapy
- DRUG etanercept
Study Locations (1)
California
- UCSF Psoriasis and Skin Treatment Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-03 |
| Phase | NA |
What the finished NCT00800982 record still lists
NCT00800982 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Narrow band (310-312 nm) ultraviolet light B phototherapy is the first listed.
NCT00800982 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00800982 about?
NCT00800982 is a clinical study titled "Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis". This is a single-center, open-label, pilot study. A total of 30 subjects (15 in each study arm) will be enrolled in this 6 month study to evaluate whether the addition of narrow band UVB (NB-UVB) phototherapy can enhance the efficacy of etanercept's maintenance dose, 50 mg once a week, in obese psor...
What is the current status of trial NCT00800982?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2008-10. Estimated completion is 2012-03.
What conditions does trial NCT00800982 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT00800982?
The interventions under investigation include: Narrow band (310-312 nm) ultraviolet light B phototherapy (PROCEDURE), etanercept (DRUG).
Who is sponsoring clinical trial NCT00800982?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00800982 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00800982's enrollment target sits among peer trials
30 95th of 125 higher than 26 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
RECRUITING · NA
-
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
RECRUITING · NA
-
A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis
RECRUITING · NA
-
Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors
RECRUITING · NA
-
Deucravacitinib Adherence Study
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia